SG11201408453PA - Methods for determining personalized treatment compositions for prostate cancer and breast cancer - Google Patents
Methods for determining personalized treatment compositions for prostate cancer and breast cancerInfo
- Publication number
- SG11201408453PA SG11201408453PA SG11201408453PA SG11201408453PA SG11201408453PA SG 11201408453P A SG11201408453P A SG 11201408453PA SG 11201408453P A SG11201408453P A SG 11201408453PA SG 11201408453P A SG11201408453P A SG 11201408453PA SG 11201408453P A SG11201408453P A SG 11201408453PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- treatment
- timeo
- breast cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- 238000006697 Forster synthesis reaction Methods 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000272534 Struthio camelus Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 9 January 2014 (09.01.2014) WIPOIPCT (10) International Publication Number WO 2014/007661 A1 (51) International Patent Classification: G01N 33/574 (2006.01) CI2N 5/09 (2010.01) C12N 5/0783 (2010.01) A61K38/16 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/NZ2013/000115 3 July 2013 (03.07.2013) English English (30) Priority Data: 61/668,395 5 July 2012 (05.07.2012) US (71) Applicant: CALDERA HEALTH LTD. [NZ/NZ]; PO Box 11664, Ellerslie, Auckland 1542 (NZ). (72) Inventors: WATSON, James, Douglas; 18 Eltham Road, Apartment 3, Kohimarama, Auckland 1071 (NZ). FOR- STER, Richard, Llewellyn, Sydney; 263 Ostrich Road, Patumahoe, Pukekohe 2679 (NZ). (74) Agent: IN-LEGAL LIMITED; PO Box 8026, The Ter race, Wellington 6143 (NZ). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER l> o o FIGURE 7A 50 45 40 35 30 25 20 15 10 5 0 t ; TimeO 3 wks jHealthy^ealthy TimeO Week 3; •TimeO 3wks TimeO Week3 CaP CaP iHeaithyNealthy CaP CaP CD8+T ceils CD4+T cells o CJ o & (57) Abstract: The present disclosure provides methods for selecting treatment a composition, or therapy, for the treatment of a can cer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering combination of a at least two components selected from immune cell activating agents, such as GM-CSF, and antigen display enhancing agents, such as keto - conazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for mon itoring the efficacy of the treatment composition during a treatment period.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668395P | 2012-07-05 | 2012-07-05 | |
| PCT/NZ2013/000115 WO2014007661A1 (en) | 2012-07-05 | 2013-07-03 | Methods for determining personalized treatment compositions for prostate cancer and breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408453PA true SG11201408453PA (en) | 2015-01-29 |
Family
ID=49878695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408453PA SG11201408453PA (en) | 2012-07-05 | 2013-07-03 | Methods for determining personalized treatment compositions for prostate cancer and breast cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8784795B2 (en) |
| EP (1) | EP2870480A4 (en) |
| JP (1) | JP2015524252A (en) |
| CN (1) | CN104884960A (en) |
| AU (1) | AU2013285626A1 (en) |
| CA (1) | CA2877872A1 (en) |
| SG (1) | SG11201408453PA (en) |
| WO (1) | WO2014007661A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| CN110804643B (en) * | 2019-10-29 | 2022-06-21 | 同济大学 | Method for evaluating influence of BCG (bacillus calmette guerin) on neutrophil activity in vitro |
| CN112608903A (en) * | 2020-12-24 | 2021-04-06 | 杭州中赢生物医疗科技有限公司 | Lymphocyte and culture system and culture method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
| JP2007501608A (en) | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | Sensitivity test to estimate the efficacy of anticancer treatment |
| WO2005046686A1 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
| US20070059319A1 (en) * | 2005-09-15 | 2007-03-15 | Caliper Life Sciences, Inc. | Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants |
| US20110286960A1 (en) * | 2008-11-02 | 2011-11-24 | Optimata Ltd. | Cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf) |
-
2013
- 2013-07-03 JP JP2015520102A patent/JP2015524252A/en active Pending
- 2013-07-03 EP EP13813993.6A patent/EP2870480A4/en not_active Withdrawn
- 2013-07-03 CA CA2877872A patent/CA2877872A1/en not_active Abandoned
- 2013-07-03 US US13/935,355 patent/US8784795B2/en not_active Expired - Fee Related
- 2013-07-03 CN CN201380045922.8A patent/CN104884960A/en active Pending
- 2013-07-03 SG SG11201408453PA patent/SG11201408453PA/en unknown
- 2013-07-03 AU AU2013285626A patent/AU2013285626A1/en not_active Abandoned
- 2013-07-03 WO PCT/NZ2013/000115 patent/WO2014007661A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2877872A1 (en) | 2014-01-09 |
| US8784795B2 (en) | 2014-07-22 |
| CN104884960A (en) | 2015-09-02 |
| JP2015524252A (en) | 2015-08-24 |
| WO2014007661A1 (en) | 2014-01-09 |
| US20140010777A1 (en) | 2014-01-09 |
| AU2013285626A1 (en) | 2015-01-22 |
| EP2870480A1 (en) | 2015-05-13 |
| EP2870480A4 (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201807188VA (en) | Modified cells for immunotherapy | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201406625XA (en) | Anti-fcrn antibodies | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
| SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |